Puma Biotechnology

PBYI · Nasdaq · United States

Share price · PBYI

$7.22-2.02 (-21.86%) 3M

close as of 2026-11-18 · 24h delayed · vol 454K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PBYI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026-15.6%
  2. 28 Oct 2026-2.7%
  3. 24 Sep 2026+5.8%
  4. 7 Aug 2026+9.7%
  5. 22 Jul 2026-8.3%
  6. 7 Jul 2026-3.2%
  7. 15 Jun 2026-3.5%
  8. 2 Mar 2026+12.6%
  9. 27 Feb 2026-25.0%

Share of unusual movement by asset

For each asset, the share of PBYI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—75%

No dated announcements about its assets since 2 Jul 2024.

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
EGFR/HER2Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer
Phase 2
Aurora kinase A (AURKA)Small molecule
Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
AlisertibPhase 2Small Cell Lung Cancer
Est. primary completion 2027-10-30 · NCT06095505 · CT.gov ↗
What to watch
December 2027 (1)
AlisertibPhase 2Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Est. primary completion 2027-12-30 · NCT06369285 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
AlisertibPhase 2Small Cell Lung Cancer ( SCLC )
Est. primary completion 2028-03-31 · NCT07465757 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$55M$18M$42M+ $67M short-term inv.—$15M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$57M$19M$37M+ $57M short-term inv.—$1.6M operating cash flowreport ↗
2026-Q1$45M$20M$36M+ $65M short-term inv.$3.8M$15M operating cash flowreport ↗
2025-Q3$54M$16M$54M+ $41M short-term inv.—$9.7M operating cash flowreport ↗
2025-Q2$52M$15M$55M+ $41M short-term inv.—$14M operating cash flowreport ↗
2025-Q1$46M$14M$63M+ $30M short-term inv.—$3.6M operating cash flowreport ↗
2024-Q3$81M$13M$67M+ $29M short-term inv.—$11M operating cash flowreport ↗
2024-Q2$47M$14M$67M+ $30M short-term inv.$4.5M$1.0M operating cash flowreport ↗
2024-Q1$44M$14M$77M+ $30M short-term inv.$4.8M$11M operating cash flowreport ↗
2023-Q3$56M$11M$82M+ $3.2M short-term inv.—$11M operating cash flowreport ↗
2023-Q2$55M$13M$60M+ $14M short-term inv.—$3.3M operating cash flowreport ↗
2023-Q1$53M$13M$61M+ $9.8M short-term inv.—$2.6M operating cash flowreport ↗
2022-Q3$57M$11M$78M+ $0 short-term inv.$0.4M$17M operating cash flowreport ↗
2022-Q2$60M$12M$53M+ $8.0M short-term inv.—-$14M operating cash flowreport ↗
2022-Q1$46M$15M$64M+ $10.0M short-term inv.$3.4M-$27M operating cash flowreport ↗
2021-Q3$46M$19M$64M+ $24M short-term inv.$45M$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$228M$62M$30M+ $68M short-term inv.—$42M operating cash flowreport ↗

For fiscal year 2025, Puma Biotechnology reported revenue of $228.37M, down 0.9% YoY from $230.47M, and R&D spend of $62.07M, up 13.0% YoY from $54.94M. Cash and equivalents were $29.64M at year-end; net income/loss and quarterly net burn were not disclosed in the provided figures.

The company continues to commercialize NERLYNX (neratinib) for HER2-positive breast cancer in the U.S. through a direct sales force and outside the U.S. through sub-licensees, with approvals in more than 40 countries. It also holds worldwide rights to alisertib, an Aurora Kinase A inhibitor in-licensed from Takeda, and intends to initially develop it in small cell lung cancer and hormone receptor-positive breast cancer, including biomarker-focused populations such as c-Myc amplification and RB1 loss/mutations.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$230M$55M$69M+ $32M short-term inv.—$39M operating cash flowreport ↗
2023-FY$236M$50M$85M+ $11M short-term inv.—$27M operating cash flowreport ↗
2022-FY$228M$52M$76M+ $4.9M short-term inv.—-$16M operating cash flowreport ↗
2021-FY$253M$72M$63M+ $19M short-term inv.$7.3M$21M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 17 sales ($2.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11MILLER MICHAEL PATRICK · directorOpen-market sale15,000$8.10$121KForm 4
2026-09-14Cesano Alessandra · directorOption exercise50,000$2.93$147KForm 4
2026-09-14WILSON TROY EDWARD · directorOpen-market sale5,000$9.10$46KForm 4
2026-09-14Cesano Alessandra · directorOpen-market sale62,150$9.12$567KForm 4
2026-09-14Cesano Alessandra · directorOption exercise (derivative)50,000——Form 4
2026-07-06NOUGUES MAXIMO F · Chief Financial OfficerOpen-market sale9,386$8.26$78KForm 4
2026-07-06HUNT DOUGLAS M · See RemarksOpen-market sale8,460$8.26$70KForm 4
2026-07-06AUERBACH ALAN H · director, President and CEO, 10% ownerOpen-market sale44,058$8.26$364KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 156 reporting institutions held 37.9M shares ($220.8M, 73.2% of shares outstanding).

#InstitutionSharesValue
1ACORN CAPITAL ADVISORS, LLC4,131,299$26.4M
2BlackRock, Inc.3,598,952$23.0M
3RENAISSANCE TECHNOLOGIES LLC1,942,413$12.4M
4AMERICAN CENTURY COMPANIES INC1,916,346$12.2M
5VANGUARD CAPITAL MANAGEMENT LLC1,817,681$11.6M
6VANGUARD PORTFOLIO MANAGEMENT LLC1,734,649$11.1M
7MILLENNIUM MANAGEMENT LLC1,477,519$9.4M
8DIMENSIONAL FUND ADVISORS LP1,436,106$9.2M
9O'SHAUGHNESSY ASSET MANAGEMENT, LLC1,138,169$7.3M
10GEODE CAPITAL MANAGEMENT, LLC1,017,342$6.5M
11STATE STREET CORP917,590$5.9M
12KENNEDY CAPITAL MANAGEMENT LLC889,601$5.7M
13AQR CAPITAL MANAGEMENT LLC800,194$5.1M
14Connor, Clark & Lunn Investment Management Ltd.782,798$5.0M
15BRIDGEWAY CAPITAL MANAGEMENT, LLC775,341$5.0M